Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8 + Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results
Ferrarotto, Renata, Bell, Diana, Rubin, Maria L, Hutcheson, Katherine A, Johnson, Jason M, Goepfert, Ryan P, Phan, Jack, Elamin, Yasir Y, Torman, Danice K, Warneke, Carla L, Hessel, Amy C, Garden, Adam S, Myers, Jeffrey N, Johnson, Faye M, Lee, J Jack, Sikora, Andrew G, Gillison, Maura L, Glisson, Bonnie S, Gross, Neil D
Published in Clinical cancer research (01.07.2020)
Published in Clinical cancer research (01.07.2020)
Get full text
Journal Article
MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator’s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma
Mateos, Maria-Victoria, Bahlis, Nizar J., Costa, Luciano J., Perrot, Aurore, Pei, Lixia, Rubin, Maria L., Lantz, Kristen, Sun, Weili, Jaffe, Mindy, Kobos, Rachel, Nooka, Ajay K.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article